To determine if patients with myasthenia gravis (MG) have antibodies to agrin, a
proteoglycan released by motor neurons and is critical for neuromuscular junction (NMJ) …

Objective: Because the extracellular matrix protein agrin is essential for neuromuscular
junction formation and maintenance, we tested the hypothesis that autoantibodies against …

Myasthenia gravis (MG) is a common disorder that affects the neuromuscular junction. It is
caused by antibodies against acetylcholine receptor and muscle‐specific tyrosine kinase; …

Objectives To determine whether patients with myasthenia gravis (MG) have serum
antibodies to lipoprotein-related protein 4 (LRP4), a newly identified receptor for agrin that is …

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction (NMJ).
Most cases of MG are caused by autoantibodies against the acetylcholine receptor (AChR) …

Myasthenia gravis (MG) is mostly caused by anti-acetylcholine receptor (AChR) auto-
antibodies (Abs). Such Abs are undetectable in 10–15% of MG patients, but many have anti …

We describe a severe form of congenital myasthenic syndrome (CMS) caused by two
heteroallelic mutations: a nonsense and a missense mutation in the gene encoding agrin …

Myasthenia gravis (MG) is an autoimmune disorder characterized by a defect in synaptic
transmission at the neuromuscular junction causing fluctuating muscle weakness with a …

The increasing understanding of the structural complexity of the neuromuscular junction
(NMJ), and the processes that are important in its development, suggests many possible …

Background and Objective To determine whether human anti-LRP4/agrin antibodies are
pathogenic in mice and to investigate underpinning pathogenic mechanisms. Methods …